# Neurology (neuromuscular) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lou Gehrig (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET018-SYN
- Date: 2026-05-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Priscilla Nakamura, MD
- Calendar frame: modern shifted

- Requested by: Gavin Hollister, MD

## Reason for consultation

Progressive weakness and loss of coordination over about a year in a 35-year-old professional baseball player, with hand wasting, widespread fasciculations, weakness of grip and left ankle dorsiflexion, brisk reflexes with spread and Hoffmann signs, and normal sensation. I am concerned about a motor neuron disease. Please evaluate with EMG and nerve conduction studies, exclude treatable mimics, and advise on diagnosis and care. **S**

## History

Mr. Gehrig, a 35-year-old professional baseball player, is seen at the request of Dr. Hollister for about a year of progressive weakness and loss of coordination, beginning with a decline in his play and progressing to fumbling with buttons, tripping on curbs and a fall on the ice, with cramps and twitching. He stopped playing two weeks ago. He has no sensory symptoms, neck pain, eye symptoms, or trouble speaking, swallowing or breathing. He has had several concussions in his career without lasting symptoms. No family history of ALS or dementia is known to him. **S**

## Examination

| System | Finding |
|---|---|
| Motor | Wasting of the first dorsal interosseous and thenar muscles, left more than right; fasciculations in both arms, thighs and calves; grip and finger abduction 4/5 on the right and 4-/5 on the left; left ankle dorsiflexion 4-/5 |
| Reflexes | Brisk with spread in the arms and legs; Hoffmann sign present on both sides; left plantar extensor; jaw jerk normal |
| Bulbar | Speech and tongue normal; no facial weakness |
| Sensory | Normal to light touch, pinprick, vibration and position |
| Respiratory | Seated FVC 4.52 L (88%); maximal inspiratory pressure -86 cmH2O |

BP 122/76 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 89.2 kg; BMI 26.6 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Hollister's intake note. MRI of the brain and cervical spine last week: normal, with no cord compression or structural lesion. Calcium 9.4 mg/dL, vitamin B12 512 pg/mL, TSH 1.6 mIU/L, A1c 5.2%, creatine kinase 412 U/L; serum protein electrophoresis with immunofixation shows no monoclonal protein; HIV test negative. Seated FVC 4.62 L (90%) at intake. EMG and nerve conduction studies this morning: normal sensory responses; reduced motor amplitudes in the median and ulnar nerves with normal conduction velocities and no conduction block; fibrillation potentials, positive sharp waves, fasciculation potentials and large, unstable motor units in the cervical (biceps, first dorsal interosseous), thoracic paraspinal, and lumbosacral (tibialis anterior, vastus lateralis) regions; bulbar muscles not yet affected. Forced vital capacity (seated): 4.52 L; Forced vital capacity, percent predicted (seated): 88%; ALSFRS-R total (0 to 48): 42; PHQ-9: 7. All results are synthetic.

## Assessment

1. **Amyotrophic lateral sclerosis, limb onset** (G12.21). Progressive motor weakness over about a year with upper and lower motor neuron signs in the cervical and lumbosacral regions, and EMG evidence of active and chronic denervation in three regions with normal sensory conduction and no conduction block. Cervical myelopathy and structural lesions are excluded by MRI; multifocal motor neuropathy by the absence of conduction block and the upper motor neuron signs; myopathy by the EMG pattern and the modest creatine kinase; and metabolic, paraproteinemic and infectious mimics by the blood tests. This meets the Gold Coast criteria and the revised El Escorial category of clinically probable ALS. ALSFRS-R 42 and FVC 88% of predicted. His past concussions do not change the diagnosis or treatment. **S**

## Recommendations

1. Diagnosis of ALS given to him in person today, with time for questions and written information.
2. Riluzole 50 mg twice daily, with ALT monthly for 3 months and then every 3 months.
3. Genetic testing for ALS-associated genes with genetic counseling today; tofersen only if an SOD1 variant is found.
4. Edaravone discussed as an option with modest evidence in a selected group of patients; he chose to begin with riluzole alone and revisit it.
5. Multidisciplinary ALS clinic every 2 to 3 months: ALSFRS-R, seated FVC and maximal inspiratory pressure, weight and swallowing at every visit; cognitive and behavioral screening; PHQ-9.
6. Noninvasive ventilation when FVC falls below 50% of predicted, maximal inspiratory pressure is weaker than -60 cmH2O, overnight oximetry shows desaturation, or orthopnea appears; supine FVC and overnight oximetry when values fall.
7. Nutrition with the dietitian to hold weight; discuss gastrostomy early, while FVC is above 50%.
8. Physical and occupational therapy for an ankle-foot orthosis, a cane, hand aids and home safety; early power wheelchair evaluation.
9. Social work for work accommodations and benefits; psychology as he wishes; advance care planning early and revisited.

## Strengths and supports

- Strengths and supports: disciplined, steady and modest; used to training and working with a team; financially secure; a close household and many friends in the game **S**

## Communication

Discussed with Dr. Hollister, who joined for the diagnosis conversation. Mr. Gehrig heard the result first, without family present, as he asked, and decided who else would be told and when. He agreed to start riluzole and to genetic testing. He decides who receives this note. **S**

## Follow-up

Genetic counselor with the result in about four weeks. First full ALS clinic visit in about five weeks, then every 2 to 3 months; primary care with Dr. Hollister in step with the clinic. **S**

## Guideline basis

- Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review) (2009), American Academy of Neurology (Neurology)
- Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review) (2009), American Academy of Neurology (Neurology)
- A proposal for new diagnostic criteria for ALS (Gold Coast criteria) (2020), Clinical Neurophysiology
- El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis (2000), World Federation of Neurology (Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders)
- Evidence-based consensus guidelines for ALS genetic testing and counseling (2023), Annals of Clinical and Translational Neurology
- Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS (2022), New England Journal of Medicine
